Recent 8-K filings for IMA

• May 07, 2026 23:59 UTC earnings materiality 0.60 neutral item 2.02item 9.01

  ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement

  Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.

• Apr 13, 2026 23:59 UTC other_material materiality 0.70 neutral item 1.01item 3.02item 9.01

  ImageneBio raises ~$30M via pre-funded warrants to fund atopic dermatitis and alopecia areata programs

  Gross proceeds of ~$30M from sale of pre-funded warrants for 5.77M shares at $5.199 each.

• Mar 10, 2026 23:59 UTC other_material materiality 0.65 neutral item 2.02item 9.01

  ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027

  Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.

• Dec 18, 2025 23:59 UTC leadership materiality 0.60 neutral item 5.02

  Imagenebio CMO Yufang Lu resigns effective Dec 31, 2025; search underway

  Yufang Lu, M.D., Ph.D., Chief Medical Officer, resigned effective December 31, 2025.

• Nov 12, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment

  Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.

• Oct 10, 2025 23:59 UTC leadership materiality 0.70 neutral item 5.02

  CFO Jotin Marango resigns effective Oct 20; search for replacement begun

  CFO Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025.

• Aug 12, 2025 23:59 UTC other_material materiality 0.75 negative item 2.01item 9.01

  ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash

  Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.

• Jul 29, 2025 23:59 UTC m_and_a materiality 0.90 neutral item 2.01item 1.01item 3.02item 9.01item 5.02item 3.03item 5.01item 5.03item 5.06item 7.01

  Ikena completes reverse merger with Inmagene, becomes ImageneBio; focuses on IMG-007 for atopic dermatitis

  Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.

• Jul 25, 2025 23:59 UTC m_and_a materiality 0.95 positive item 7.01item 9.01

  Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement

  Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.

• Jul 15, 2025 23:59 UTC m_and_a materiality 0.80 neutral item 5.02item 5.07item 8.01item 9.01

  Ikena stockholders approve Inmagene merger; 1:12 reverse split; combined co. to trade as IMA

  All 7 proposals approved including merger issuance of IKNA shares >20% and reverse split.

• Jul 11, 2025 23:59 UTC m_and_a materiality 0.60 positive item 8.01item 9.01

  ISS and Glass Lewis recommend Ikena stockholders vote FOR Inmagene merger

  Institutional Shareholder Services (ISS) and Glass Lewis recommend voting FOR share issuance related to merger with Inmagene.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.55 · Most common event other_material

2 positive 1 negative 20 neutral

source · IMA on sec.gov